Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)

Phase 3

Active, not recruiting

Conditions: Genital Warts

Interventions: Biological: 9vHPV vaccine

First Posted Date: 2022-04-06

Last Posted Date: 2023-01-19

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1590

Registration Number: NCT05314023

Locations: 🇨🇳
Center for Disease Control and Prevention of Rong An ( Site 0006), Liuzhou, Guangxi, China
🇨🇳
Santai County Center for Disease Control and Prevention ( Site 0001), Mianyang, Sichuan, China
🇨🇳
Liucheng County Centers for Disease Control and Prevention ( Site 0005), Liuzhou, Guangxi, China

and more 2 locations

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

Phase 3

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Biological: pembrolizumab/vibostolimab
Biological: durvalumab
Drug: cisplatin
Drug: pemetrexed
Drug: etoposide
Drug: carboplatin
Drug: paclitaxel
Radiation: thoracic radiotherapy

First Posted Date: 2022-03-28

Last Posted Date: 2025-03-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 611

Registration Number: NCT05298423

Locations: 🇺🇸
VA Long Beach Healthcare System ( Site 2831), Long Beach, California, United States
🇺🇸
VA West Los Angeles Medical Center ( Site 2808), Los Angeles, California, United States
🇺🇸
Millennium Oncology Research Clinic ( Site 2801), Hollywood, Florida, United States

and more 157 locations

Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016)

Phase 4

Completed

Conditions: Hexavalent Vaccine
Vaccines, Combined

Interventions: Biological: Vaxelis™

First Posted Date: 2022-03-21

Last Posted Date: 2024-07-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 168

Registration Number: NCT05289271

Locations: 🇩🇪
Private Practice - Dr. Petri, Kinderarztpraxis ( Site 0056), Huerth, Nordrhein-Westfalen, Germany
🇩🇪
Gemeinschaftspraxis Dres. Adelt, Mettlich-Lambrecht und Denneberg ( Site 0053), Bramsche, Niedersachsen, Germany
🇩🇪
Kinderärztliche Gemeinschaftspraxis ( Site 0057), Wolfsburg, Niedersachsen, Germany

and more 10 locations

Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)

Phase 3

Active, not recruiting

Conditions: Papillomavirus Infections

Interventions: Other: Placebo
Biological: 9vHPV Vaccine

First Posted Date: 2022-03-18

Last Posted Date: 2024-12-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 8100

Registration Number: NCT05285826

Locations: 🇨🇳
Beijing Youan Hospital ( Site 0001), Bejing, Beijing, China
🇨🇳
The Second Affiliated Hospital Chongqing Medical University ( Site 0052), Chongqing, Chongqing, China
🇨🇳
Southern Medical University Nanfang Hospital-Center for Drug Clinical Research ( Site 0031), Guangzhou, Guangdong, China

and more 31 locations

A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)

Phase 2

Completed

Conditions: Hypercholesterolemia
Familial Hypercholesterolemia

Interventions: Drug: Enclitide Chloride
Drug: Placebo

First Posted Date: 2022-03-02

Last Posted Date: 2024-12-09

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 381

Registration Number: NCT05261126

Locations: 🇺🇸
Dallas Diabetes Research Center ( Site 0012), Dallas, Texas, United States
🇺🇸
Center for Cardiometabolic Disease Prevention/Baylor College of Medicine ( Site 0051), Houston, Texas, United States
🇺🇸
Midwest Institute For Clinical Research ( Site 0036), Indianapolis, Indiana, United States

and more 60 locations

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

Phase 3

Recruiting

Conditions: Colorectal Neoplasms

Interventions: Drug: Oxaliplatin
Biological: Pembrolizumab
Drug: Leucovorin
Drug: 5-fluorouracil
Drug: Irinotecan
Biological: Bevacizumab
Biological: Cetuximab

First Posted Date: 2022-02-15

Last Posted Date: 2025-05-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 100

Registration Number: NCT05239741

Locations: 🇨🇳
Guangxi Medical University Affiliated Tumor Hospital ( Site 0039), Nanning, Guangxi, China
🇨🇳
The Third Xiangya Hospital of Central South University ( Site 0031), Changsha, Hunan, China
🇨🇳
The Affiliated Jiangyin Hospital of Southeast University Medical College ( Site 0037), Jiangyin, Jiangsu, China

and more 29 locations

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

Phase 3

Active, not recruiting

Conditions: Carcinoma, Renal Cell

Interventions: Biological: Pembrolizumab
Drug: Belzutifan
Drug: Placebo

First Posted Date: 2022-02-15

Last Posted Date: 2025-01-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1800

Registration Number: NCT05239728

Locations: 🇺🇸
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus, Ohio, United States
🇺🇸
UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro, Los Angeles, California, United States
🇺🇸
UT Southwestern Medical Center ( Site 3529), Dallas, Texas, United States

and more 282 locations

MK-8189 Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: MK-8189
Drug: Placebo

First Posted Date: 2022-02-07

Last Posted Date: 2023-01-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 29

Registration Number: NCT05227118

Locations: 🇺🇸
CITrials ( Site 0007), Santa Ana, California, United States
🇺🇸
iResearch Atlanta ( Site 0009), Decatur, Georgia, United States
🇺🇸
Global Medical Institutes LLC; Princeton Medical Institute ( Site 0008), Princeton, New Jersey, United States

and more 5 locations

Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

Phase 3

Active, not recruiting

Conditions: Metastatic Non-Small Cell Lung Cancer

Interventions: Biological: Pembrolizumab/Vibostolimab
Drug: Carboplatin
Drug: Cisplatin
Drug: Paclitaxel
Drug: Nab-paclitaxel
Drug: Pemetrexed
Biological: Pembrolizumab

First Posted Date: 2022-02-07

Last Posted Date: 2025-02-11

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 739

Registration Number: NCT05226598

Locations: 🇪🇸
Hospital Clinico San Carlos-Oncology Department ( Site 1107), Madrid, Spain
🇨🇳
Jilin Cancer Hospital-oncology department ( Site 2603), Changchun, Jilin, China
🇨🇳
Zhejiang Cancer Hospital-Oncology ( Site 2612), Hangzhou, Zhejiang, China

and more 146 locations

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

Phase 3

Active, not recruiting

Conditions: Small Cell Lung Carcinoma

Interventions: Biological: Pembrolizumab/Vibostolimab Co-Formulation
Drug: Saline placebo
Drug: Cisplatin
Drug: Etoposide
Biological: Atezolizumab
Drug: Carboplatin

First Posted Date: 2022-02-04

Last Posted Date: 2025-05-30

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 460

Registration Number: NCT05224141

Locations: 🇯🇵
National Cancer Center Hospital East ( Site 3002), Kashiwa, Chiba, Japan
🇨🇦
Lakeridge Health ( Site 0102), Oshawa, Ontario, Canada
🇩🇪
LungenClinic Grosshansdorf-Onkologie ( Site 0903), Grosshansdorf, Schleswig-Holstein, Germany

and more 137 locations

Home Terms & Conditions Privacy Policy